It's old hat that biotech ETFs are beating the stock market. But three are new launches flying under the radar of many investors. BioShares Biotechnology Products (BBP) holds stocks such as Celgene (CELG) and Anacor Pharmaceuticals (ANAC) that have shone of late. Two others focus on businesses in the clinical trial stage. "These are very innovative ETFs investing in companies at the cutting edge of medical research," says Neena Mishra, director of
Thursday 16 July 2015
Is Your Biotech ETF Keeping Up With 3 New Standouts?
Otmane El Rhazi from Investor's Business Daily - ETFs RSS.
It's old hat that biotech ETFs are beating the stock market. But three are new launches flying under the radar of many investors. BioShares Biotechnology Products (BBP) holds stocks such as Celgene (CELG) and Anacor Pharmaceuticals (ANAC) that have shone of late. Two others focus on businesses in the clinical trial stage. "These are very innovative ETFs investing in companies at the cutting edge of medical research," says Neena Mishra, director of
It's old hat that biotech ETFs are beating the stock market. But three are new launches flying under the radar of many investors. BioShares Biotechnology Products (BBP) holds stocks such as Celgene (CELG) and Anacor Pharmaceuticals (ANAC) that have shone of late. Two others focus on businesses in the clinical trial stage. "These are very innovative ETFs investing in companies at the cutting edge of medical research," says Neena Mishra, director of
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment